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Despite advances in hematopoietic stem cell transplantation (HSCT) for the treatment of hematologic
malignancies, relapse remains the leading cause of death after transplant. Biologic and clinical investigations
are needed to combat this primary cause of death after transplantation. The National Cancer Institute held
international workshops in 2009 and 2012 to help address this problem. Three major initiatives for coordi-
nated research were proposed: 1) To establish multicenter networks for basic, translational, epidemiologic
and clinical research; 2) To establish a network of biorepositories for the collection of samples before and
after HSCT to aid in laboratory and clinical studies; and 3) To reﬁne, implement and study proposed deﬁ-
nitions for disease-speciﬁc response and relapse and for monitoring of minimal residual disease. The
workshop in 2012 also featured nine presentations, summaries of which follow in three manuscripts.
 2013 American Society for Blood and Marrow Transplantation.Advances in the science and technology of hematopoietic
stem cell transplantation (HSCT) have led to improved
transplantation outcomes almost exclusively through the
reduction of transplantation-related mortality. Despite con-
tinued progress, there has been only a minimal change in the
incidence of post-transplantation relapse, which remains the
leading cause of death after HSCT [1].
To address this problem, the National Cancer Institute
(NCI) organized 2 international workshops on this subject.
The goals of the ﬁrst workshop, held in 2009, were to review
the state of the science and to generate recommendations for
research efforts [2-10]. Three major initiatives for coordi-
nated research were proposed: (1) to establish multicenter
networks for basic, translational, epidemiologic, and clinical
research; (2) to establish a network of biorepositories for
the collection of samples before and after HSCT to aid labo-
ratory and clinical studies; and (3) to reﬁne, implement, and
study proposed deﬁnitions for disease-speciﬁc response
and relapse and for monitoring of minimal residual disease
(MRD) [10]. The overarching goals of the second NCIedgments on page 1535.
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13.08.016workshop, held in 2012, were to advance those recommen-
dations (Table 1).
To facilitate the development and coordination of multi-
center studies and post-transplantation relapse clinical trials
networks, a Protocol Planning Committee, 3 Protocol
Development Teams (Biology, Prevention, and Treatment)
and multiple Study Teams were assembled during the
planning and preparation stages of the second NCI work-
shop. Protocol concepts were developed in advance and
presented at theworkshop for further reﬁnement. Additional
aims of the second workshop were to update the current
state of the science and to provide a forum for the presen-
tation and review of research related to the biology and
clinical studies of relapse. Attendees included 180 individ-
uals from 9 countries. Fifty-seven scientiﬁc abstracts were
presented as part of the Scientiﬁc Education Program. The
agenda, presentations, and abstracts are available on the
workshop Web site: https://ccrod.cancer.gov/conﬂuence/
display/2012NCIRelapse/Home.
The workshop featured 9 keynote presentations,
summaries of which follow in 3 parts. In Part I, “Biology of
Relapse after Transplantation,” recent advances in under-
standing host, disease, and transplantation-related contri-
butions to relapse are reviewed, including the biology of the
therapeutic graft-versus-malignancy effect, immunologic
homeostasis and reconstitution, the tumor microenviron-
ment, and clonal escape. Part II, “Relapse Prevention using
Novel Agents and Immunomodulatory Strategies,” representsTransplantation.
Table 1
Goals of the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell
Transplantation
Protocol development goals
1. To establish multicenter networks for basic, translational, epidemiologic, and clinical research
 Leverage and integrate existing networks, consortia, organizations, and agencies
 Align investigators and institutions with established research interests
 Promote ongoing research activities
2. To help address key issues
 Funding
 Infrastructure
 Access to new agents
 Trial design, statistical challenges
 Central laboratory monitoring for novel endpoints and biomarkers
 Data collection and reporting
Biorepository establishment goals
1. To facilitate the establishment of a network of biorepositories for the collection of samples before and after HSCT to aid in laboratory and clinical studies
2. To promote the collection of human samples
 Pretransplantation and post-transplantation malignant cells
 Allografts
 Blood at set time points post-transplantation and at relapse
3. To establish standards for collection, storage, utilization, and distribution
4. To help coordinate investigators and institutions with established repositories
Disease-speciﬁc response and relapse deﬁnitions and monitoring goals
1. To reﬁne, implement, and study proposed deﬁnitions for disease-speciﬁc response and relapse and for monitoring of MRD
2. To incorporate sensitive evaluation methods into clinical trials
 Determine the clinical relevance of MRD surveillance in speciﬁc diseases
 Assess the impact of interventional strategies after detection of MRD
3. To work toward increased data collection, standardization, and reporting speciﬁcally related to relapse after HSCT
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autologous HSCT. The roles of novel agents and immuno-
modulatory strategies in management of relapse of multiple
myeloma are discussed, with broader consideration of areas
relevant for relapse of othermalignancies and after allogeneic
HSCT, including tumor vaccine strategies, approaches to
overcome tumor-associated immunosuppression and toler-
ance, and natural killer cell biology and therapies. Part III,
“Prevention and Treatment,” addresses newer agents, donor
lymphocyte infusions, and novel cellular therapies to
enhance graft-versus-tumor activity.
There is reason for optimism in the study and treatment
of post-transplantation relapse. Whole-genome sequencing
has opened an entirely new approach to study malignant
progression and relapse [11,12]. MRD detection and early
intervention have proven beneﬁcial in speciﬁc diseases [7,8].
A growing number of clinical trials focused on relapse after
HSCT are in development or underway. The results of the
Cancer and Leukemia Group B 100104 and the Intergroupe
Francophone du Myélome 99-02 trials should encourage us
to fulﬁll the main goal of this second workshop, which is to
develop a portfolio of treatment, prevention, and tissue
acquisition protocols to move the ﬁeld forward and to ﬁrmly
establish the required infrastructure to perform such work.
That the relatively simple addition of lenalidomide after an
autograft signiﬁcantly increases the post-transplantation
progression-free and event-free survival rates for individ-
uals with myeloma [13,14] suggests that additional strategies
will be effective in other diseases and transplantation
settings [15-17].
Although time and resources are limited, it is critical that
the scientiﬁc community vigorously pursue studies of the
biology of post-transplantation relapse and approaches to
combat relapse after HSCT. Only through concerted and
coordinated efforts will signiﬁcant improvements beachieved in the treatment and prevention of this primary
cause of death after HSCT.
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